What is MTNB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MTNB?

P/E (TTM) is n/a and 52-week range is $2.26 to $29.40 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MTNB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MTNB?

The company profile lists revenue (TTM) near $4M, net income (TTM) near $-2.06B, EPS (TTM) near $-1.62 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Matinas BioPharma Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Bedminster, New Jersey, US, 13.7M shares outstanding, ISIN US5768103039 when available from company profile and filing metadata.

Matinas BioPharma Holdings Inc

$MTNB

Health Care · Biotechnology

IR Run Scenarios

$2.87

+1.41%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 2 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.

Employees

Website

www.matinasbiopharma.com/

IPO

2014-06-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)